News

The primary endpoint of the eight-week study was LDL-C reduction, with secondary endpoints of HDL-C increases and effects on other lipoproteins and apolipoproteins and blood pressure evaluated across

Tiger-1 is a double-blind, placebo-controlled, randomized study comparing 60mg of Denufosol to placebo, administered three times daily by jet nebulizer, in approximately 350 patients with mild cystic fibrosis

Zybrestat, delivered in combination with Avastin, appeared safe and well-tolerated and resulted in significantly enhanced tumor blood-flow reductions as measured by DCE-MRI imaging, and demonstrated early evidence of

In the study measuring LDL-cholesterol reduction, patients treated with a combination of 10mg of Merck & Co. and Schering-Plough’s Zetia (ezetimibe) and 10mg AEGR-733, experienced LDL-C reductions of

EpiCept successfully identified the maximum tolerated dose of EPC2407 in the Phase I study. The maximum tolerated dose was well below the dose which produced the expected toxicity

The portfolio includes the dermatology products, Solaraze (3% gel diclofenac sodium) and Vaniqa (eflornithine hydrochloride), and six other non-promoted products across a range of indications, which are principally

The patent covers the formulation of pain drug Opana ER (oxymorphone HCl) extended-release tablets CII using Penwest’s TIMERx technology and is exclusively licensed to Endo Pharmaceuticals pursuant to

Having received approval, market launch is expected in the first quarter of 2008. Earlier, Dusa entered into an exclusive marketing, distribution and supply agreement with Daewoong Pharmaceutical and

The new Phase II open label study at McGill University will explore the effect of an investigational drug on patients with recurrent or advanced cancer. Researchers indicate that